Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care 英文参考文献.docVIP

/content/4/5/302 Primary research Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care Richard M Venn, John Hell and R Michael Grounds St George’s Hospital, London, UK Received: 4 July 2000 Accepted: 11 July 2000 Published: 31 July 2000 Crit Care 2000,4:302–308 ? Current Science Ltd (Print ISSN 1364-8535; Online ISSN 1466-609X) Statement of findings The respiratory effects of dexmedetomidine were retrospectively examined in 33 postsurgical patients involved in a randomised, placebo-controlled trial after extubation in the intensive care unit (ICU). Morphine requirements were reduced by over 50% in patients receiving dexmedetomidine. There were no differences in respiratory rates, oxygen saturations, arterial pH and arterial partial carbon dioxide tension (PaCO ) between the groups. Interestingly the 2 arterial partial oxygen tension (PaO ):fractional inspired oxygen (FIO ) ratios were statistically 2 2 significantly higher in the dexmedetomidine group. Dexmedetomidine provides important postsurgical analgesia and appears to have no clinically important adverse effects on respiration in the surgical patient who requires intensive care. Keywords:α2-Adrenoceptor agonist, analgesia, dexmedetomidine, intensive care, postoperative, respiratory, sedation Synopsis Introduction: Theα2-agonist dexmedetomidine is a new class to continue sedation with dexmedetomidine over the stressful extubation period without concerns over respiratory depression, while ensuring that haemodynamic stability is preserved. The present study is a retrospective analysis of the respiratory response to dexmedetomidine in 33 postsurgical patients (who of sedative drug that is being investigated for use in ICU settings. It is an effective agent for the management of sedation and analgesia after cardiac, general, orthopaedic, head and neck, oncological and vascular surgery in the ICU